Adelaide-Led Rocket Experiment Advances Space Medicine for Deep Space Missions

An international research team led by the University of Adelaide has successfully tested a new method to protect medicines during spaceflight, marking a significant milestone for the future of long-duration missions to the Moon and Mars.

Protecting Medicine in Extreme Conditions

The experiment, conducted in partnership with the German Aerospace Center (DLR), investigated whether a natural protective coating could preserve the stability of liquid medications subjected to the intense vibrations, gravitational forces, and weightlessness of a rocket launch. Researchers utilized chitosan—a material derived from crustaceans—to coat nanoemulsions containing melatonin, a hormone being studied for its potential to support astronaut bone health.

The samples were launched aboard the MAPHEUS-15 sounding rocket from the Esrange Space Center in Sweden in November 2024. During the flight, the medicine experienced over seven minutes of weightlessness before being recovered and returned to Adelaide for analysis.

Promising Results for Future Exploration

Post-flight analysis revealed that the chitosan-coated droplets maintained their size and predictable release patterns, whereas uncoated samples showed signs of instability. Professor Volker Hessel of the University of Adelaide noted that as space travel extends to the Moon and Mars, ensuring that medications remain safe and effective is critical, as drugs formulated for Earth may react differently to the stresses of space.

Beyond space exploration, the research team—which included collaborators from La Trobe University, the University of Nottingham, and the University of Warwick—suggests that these robust drug delivery systems could eventually improve healthcare in harsh or remote environments on Earth. The findings have been published in the journal Advanced Healthcare Materials, with further testing planned to evaluate the technology for longer-duration space missions.